Suppr超能文献

将肌动蛋白成核化合物缪兰酰胺转化为成核抑制剂。

Turning the Actin Nucleating Compound Miuraenamide into Nucleation Inhibitors.

作者信息

Wang Shuaijun, Meixner Maximilian, Yu Lushuang, Zhuo Ling, Karmann Lisa, Kazmaier Uli, Vollmar Angelika M, Antes Iris, Zahler Stefan

机构信息

Department of Pharmacy, Ludwig-Maximilians-Universität, 81377 Munich, Germany.

Computational Chemical Biology, Technische Universität München, TUM School of Life Sciences, Emil-Erlenmeyer-Forum 8, 85354 Freising, Germany.

出版信息

ACS Omega. 2021 Aug 18;6(34):22165-22172. doi: 10.1021/acsomega.1c02838. eCollection 2021 Aug 31.

Abstract

Natural compounds that either increase or decrease polymerization of actin into filaments have become indispensable tools for cell biology. However, to date, it was not possible to use them as therapeutics due to their overall cytotoxicity and their unfavorable pharmacokinetics. Furthermore, their synthesis is in general quite complicated. In an attempt to find simplified analogues of miuraenamide, an actin nucleating compound, we identified derivatives with a paradoxical inversion of the mode of action: instead of increased nucleation, they caused an inhibition. Using an extensive computational approach, we propose a binding mode and a mode of action for one of these derivatives. Based on our findings, it becomes feasible to tune actin-binding compounds to one or the other direction and to generate new synthetic actin binders with increased functional selectivity.

摘要

能够增加或减少肌动蛋白聚合成丝的天然化合物已成为细胞生物学中不可或缺的工具。然而,迄今为止,由于其总体细胞毒性和不良的药代动力学,它们无法用作治疗药物。此外,它们的合成通常相当复杂。为了寻找肌动蛋白成核化合物三肋酰胺的简化类似物,我们鉴定出了作用模式发生矛盾反转的衍生物:它们不是增加成核,而是导致抑制。通过广泛的计算方法,我们提出了其中一种衍生物的结合模式和作用模式。基于我们的发现,调整肌动蛋白结合化合物向一个或另一个方向发展,并生成具有更高功能选择性的新型合成肌动蛋白结合剂变得可行。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a171/8412923/830f649303b4/ao1c02838_0002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验